A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer
Niranjan J Sathianathen, Fernando Alarid-Escudero, Karen M Kuntz, Nathan Lawrentschuk, Damien M Bolton, Declan G Murphy, Simon P Kim, Badrinath R Konety
European Urology Oncology | ELSEVIER | Published : 2019
BACKGROUND: Following the recent publication of results from randomized trials that have demonstrated a survival benefit for the addition of docetaxel or abiraterone acetate to androgen deprivation therapy (ADT) in the treatment of metastatic prostate cancer, it is important to assess whether the benefits of treatment with these agents outweigh their costs. OBJECTIVE: To perform a cost-effectiveness analysis of immediate docetaxel or abiraterone acetate treatment in addition to ADT in men with metastatic hormone-sensitive prostate cancer (PC). DESIGN, SETTING, AND PARTICIPANTS: We developed a state-transition model to simulate the natural progression of metastatic PC. Model parameters were d..View full abstract
Niranjan J. Sathianathen and Karen M. Kuntz have received support from the Cloverfields Foundation and The Institute for Prostate and Urologic Cancers (University of Minnesota).